Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting β-catenin and AKT signaling but frequently methylated in common carcinomas

Cellular and Molecular Life Sciences

Volumn 71, Issue 11, 2014, Pages 2179-2192

  Li, Lili ^a   Ying, Jianming ^a   Tong, Xin ^b,c   Zhong, Lan ^a   Su, Xianwei ^a   Xiang, Tingxiu ^d   Shu, Xingsheng ^a   Rong, Rong ^a   Xiong, Lei ^a   Li, Hongyu ^a   Chan, Anthony T C ^a   Ambinder, Richard F ^e   Guo, Yajun ^b,c   Tao, Qian ^a,e  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d CHONGQING MEDICAL UNIVERSITY   (China)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoma; Epigenetic; Methylation; ROR2; Tumor suppressor

Indexed keywords

BETA CATENIN; PROTEIN KINASE B; WNT5A PROTEIN;

ADULT; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CARCINOMA; CELL CYCLE ARREST; CHEMOSENSITIVITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; CPG ISLAND; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGUS CARCINOMA; FETUS; GENE FUNCTION; GENE IDENTIFICATION; GENE INACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LUNG CARCINOMA; METHYLATION; NASOPHARYNX CARCINOMA; NUCLEOTIDE SEQUENCE; PRIMARY TUMOR; PROMOTER REGION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; TUMOR SUPPRESSOR GENE; TYROSINE KINASE LIKE ORPHAN RECEPTOR 2 GENE;

BETA CATENIN; CARCINOGENESIS; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84901686744     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-013-1485-z     Document Type: Article

References (53)

1. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411(6835):355-365. doi: 10.1038/35077225
2. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298(5600):1912-1934. doi: 10.1126/science.1075762
3. Gao B, Song H, Bishop K, Elliot G, Garrett L, English MA, Andre P, Robinson J, Sood R, Minami Y, Economides AN, Yang Y (2011) Wnt signaling gradients establish planar cell polarity by inducing Vangl2 phosphorylation through Ror2. Dev Cell 20(2):163-176. doi: 10.1016/j.devcel.2011.01.001
4. Oldridge M, Fortuna AM, Maringa M, Propping P, Mansour S, Pollitt C, DeChiara TM, Kimble RB, Valenzuela DM, Yancopoulos GD, Wilkie AO (2000) Dominant mutations in ROR2, encoding an orphan receptor tyrosine kinase, cause brachydactyly type B. Nat Genet 24(3):275-278. doi: 10.1038/73495
5. DeChiara TM, Kimble RB, Poueymirou WT, Rojas J, Masiakowski P, Valenzuela DM, Yancopoulos GD (2000) Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development. Nat Genet 24(3):271-274. doi: 10.1038/73488
6. Maeda K, Kobayashi Y, Udagawa N, Uehara S, Ishihara A, Mizoguchi T, Kikuchi Y, Takada I, Kato S, Kani S, Nishita M, Marumo K, Martin TJ, Minami Y, Takahashi N (2012) Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med 18(3):405-412. doi: 10.1038/nm.2653
7. Takai A, Inomata H, Arakawa A, Yakura R, Matsuo-Takasaki M, Sasai Y (2010) Anterior neural development requires Del1, a matrix-associated protein that attenuates canonical Wnt signaling via the Ror2 pathway. Development 137(19):3293-3302. doi: 10.1242/dev.051136
8. Hikasa H, Shibata M, Hiratani I, Taira M (2002) The Xenopus receptor tyrosine kinase Xror2 modulates morphogenetic movements of the axial mesoderm and neuroectoderm via Wnt signaling. Development 129(22):5227-5239
9. Ford CE, Qian Ma SS, Quadir A, Ward RL (2012) The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis. Int J Cancer. doi: 10.1002/ijc.27984
10. Wright TM, Brannon AR, Gordan JD, Mikels AJ, Mitchell C, Chen S, Espinosa I, van de Rijn M, Pruthi R, Wallen E, Edwards L, Nusse R, Rathmell WK (2009) Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene 28(27):2513-2523. doi: 10.1038/onc.2009.116
11. Yamamoto H, Oue N, Sato A, Hasegawa Y, Matsubara A, Yasui W, Kikuchi A (2010) Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene 29(14):2036-2046. doi: 10.1038/onc.2009.496
12. O'Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC, French AD, Dissanayake SK, Indig FE, Bernier M, Taub DD, Hewitt SM, Weeraratna AT (2009) The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene 29(1):34-44. doi: 10.1038/onc.2009.305
13. Ren D, Minami Y, Nishita M (2011) Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snail-mediated epithelial-mesenchymal transition. Genes Cells 16(3):304-315. doi: 10.1111/j.1365-2443.2011.01487.x
14. Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, Kawaguchi H, Myoui A, Yoshikawa H, Naka N, Araki N, Kudawara I, Ieguchi M, Nakamura K, Nakamura Y, Matsuda K (2009) Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci 100(7):1227-1233. doi: 10.1111/j.1349-7006.2009.01165.x
15. Edris B, Espinosa I, Muhlenberg T, Mikels A, Lee CH, Steigen SE, Zhu S, Montgomery KD, Lazar AJ, Lev D, Fletcher JA, Beck AH, West RB, Nusse R, van de Rijn M (2012) ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol. doi: 10.1002/path.3986
16. Lara E, Calvanese V, Huidobro C, Fernandez AF, Moncada-Pazos A, Obaya AJ, Aguilera O, Gonzalez-Sancho JM, Sanchez L, Astudillo A, Munoz A, Lopez-Otin C, Esteller M, Fraga MF (2010) Epigenetic repression of ROR2 has a Wnt-mediated, pro-tumourigenic role in colon cancer. Mol Cancer 9:170. doi: 10.1186/1476-4598-9-170
17. Geng M, Cao YC, Chen YJ, Jiang H, Bi LQ, Liu XH (2012) Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis. World J Gastroenterol 18(12):1328-1338. doi: 10.3748/wjg.v18.i12.1328
18. Grumolato L, Liu G, Mong P, Mudbhary R, Biswas R, Arroyave R, Vijayakumar S, Economides AN, Aaronson SA (2010) Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev 24(22):2517-2530. doi: 10.1101/gad.1957710
19. Mikels AJ, Nusse R (2006) Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 4(4):e115. doi: 10.1371/journal.pbio.0040115
20. Mikels A, Minami Y, Nusse R (2009) Ror2 receptor requires tyrosine kinase activity to mediate Wnt5A signaling. J Biol Chem 284(44):30167-30176. doi: 10.1074/jbc.M109.041715
21. Billiard J, Way DS, Seestaller-Wehr LM, Moran RA, Mangine A, Bodine PV (2005) The orphan receptor tyrosine kinase Ror2 modulates canonical Wnt signaling in osteoblastic cells. Mol Endocrinol 19(1):90-101. doi: 10.1210/me.2004-0153
22. Ho HY, Susman MW, Bikoff JB, Ryu YK, Jonas AM, Hu L, Kuruvilla R, Greenberg ME (2012) Wnt5a-Ror-dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis. Proc Natl Acad Sci USA 109(11):4044-4051. doi: 10.1073/pnas.1200421109
23. Schambony A, Wedlich D (2007) Wnt-5A/Ror2 regulate expression of XPAPC through an alternative noncanonical signaling pathway. Dev Cell 12(5):779-792. doi: 10.1016/j.devcel.2007.02.016
24. Oishi I, Suzuki H, Onishi N, Takada R, Kani S, Ohkawara B, Koshida I, Suzuki K, Yamada G, Schwabe GC, Mundlos S, Shibuya H, Takada S, Minami Y (2003) The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells 8(7):645-654 (pii 662)
25. Takeuchi S, Takeda K, Oishi I, Nomi M, Ikeya M, Itoh K, Tamura S, Ueda T, Hatta T, Otani H, Terashima T, Takada S, Yamamura H, Akira S, Minami Y (2000) Mouse Ror2 receptor tyrosine kinase is required for the heart development and limb formation. Genes Cells 5(1):71-78 (pii gtc300)
26. Yamamoto S, Nishimura O, Misaki K, Nishita M, Minami Y, Yonemura S, Tarui H, Sasaki H (2008) Cthrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex. Dev Cell 15(1):23-36. doi: 10.1016/j.devcel.2008.05.007
27. Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, Putti T, Murray P, Chan AT, Tao Q (2006) Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 25(7):1070-1080. doi: 10.1038/sj.onc.1209154
28. Li L, Ying J, Li H, Zhang Y, Shu X, Fan Y, Tan J, Cao Y, Tsao SW, Srivastava G, Chan AT, Tao Q (2011) The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/beta-catenin signaling and silenced in common carcinomas. Oncogene 31(34):3901-3912. doi: 10.1038/onc.2011.541
29. Seng TJ, Low JS, Li H, Cui Y, Goh HK, Wong ML, Srivastava G, Sidransky D, Califano J, Steenbergen RD, Rha SY, Tan J, Hsieh WS, Ambinder RF, Lin X, Chan AT, Tao Q (2007) The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene 26(6):934-944. doi: 10.1038/sj.onc.1209839
30. Tao Q, Huang H, Geiman TM, Lim CY, Fu L, Qiu GH, Robertson KD (2002) Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet 11(18):2091-2102
31. Tao Q, Swinnen LJ, Yang J, Srivastava G, Robertson KD, Ambinder RF (1999) Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis. Am J Pathol 155(2):619-625. doi: 10.1016/S0002-9440(10)65157-7
32. Jin H, Wang X, Ying J, Wong AH, Cui Y, Srivastava G, Shen ZY, Li EM, Zhang Q, Jin J, Kupzig S, Chan AT, Cullen PJ, Tao Q (2007) Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc Natl Acad Sci USA 104(30):12353-12358. doi: 10.1073/pnas.0700153104
33. Ying J, Li H, Yu J, Ng KM, Poon FF, Wong SC, Chan AT, Sung JJ, Tao Q (2008) WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res 14(1):55-61. doi: 10.1158/1078-0432.CCR-07-1644
34. Hu XT, Zhang FB, Fan YC, Shu XS, Wong AH, Zhou W, Shi QL, Tang HM, Fu L, Guan XY, Rha SY, Tao Q, He C (2009) Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer. Oncogene 28(26):2466-2475. doi: 10.1038/onc.2009.92
35. Wang Y, Li J, Cui Y, Li T, Ng KM, Geng H, Li H, Shu XS, Liu W, Luo B, Zhang Q, Mok TS, Zheng W, Qiu X, Srivastava G, Yu J, Sung JJ, Chan AT, Ma D, Tao Q, Han W (2009) CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res 69(12):5194-5201. doi: 10.1158/0008-5472.CAN-08-3694
36. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6(1):1-6
37. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3(6):415-428. doi: 10.1038/nrg816nrg816
38. Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6(2):107-116. doi: 10.1038/nrc1799
39. Ushijima T (2005) Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5(3):223-231. doi: 10.1038/nrc1571
40. Ying J, Srivastava G, Hsieh WS, Gao Z, Murray P, Liao SK, Ambinder R, Tao Q (2005) The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Clin Cancer Res 11(18):6442-6449. doi: 10.1158/1078-0432. CCR-05-0267
41. Qiu GH, Salto-Tellez M, Ross JA, Yeo W, Cui Y, Wheelhouse N, Chen GG, Harrison D, Lai P, Tao Q, Hooi SC (2008) The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle. J Hepatol 48(3):433-441. doi: 10.1016/j.jhep.2007.11. 015
42. Li X, Cheung KF, Ma X, Tian L, Zhao J, Go MY, Shen B, Cheng AS, Ying J, Tao Q, Sung JJ, Kung HF, Yu J (2011) Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients. Oncogene 31(29):3419-3430. doi: 10.1038/onc.2011.511
43. Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP, Tong JH, Ying JM, Jin H, To KF, Chan FK, Sung JJ (2009) Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 136(2):640 e641-651 e641. doi: 10.1053/j.gastro.2008.10.050
44. Green JL, Kuntz SG, Sternberg PW (2008) Ror receptor tyrosine kinases: orphans no more. Trends Cell Biol 18(11):536-544. doi: 10.1016/j.tcb.2008.08.006
45. Chen Y, Bellamy WP, Seabra MC, Field MC, Ali BR (2005) ER-associated protein degradation is a common mechanism underpinning numerous monogenic diseases including Robinow syndrome. Hum Mol Genet 14(17):2559-2569. doi: 10.1093/hmg/ddi259
46. Liu Y, Ross JF, Bodine PV, Billiard J (2007) Homodimerization of Ror2 tyrosine kinase receptor induces 14-3-3(beta) phosphorylation and promotes osteoblast differentiation and bone formation. Mol Endocrinol 21(12):3050-3061. doi: 10.1210/me.2007-0323
47. Kani S, Oishi I, Yamamoto H, Yoda A, Suzuki H, Nomachi A, Iozumi K, Nishita M, Kikuchi A, Takumi T, Minami Y (2004) The receptor tyrosine kinase Ror2 associates with and is activated by casein kinase iepsilon. J Biol Chem 279(48):50102-50109. doi: 10.1074/jbc.M409039200
48. Li J, Ying J, Fan Y, Wu L, Ying Y, Chan AT, Srivastava G, Tao Q (2010) WNT5A antagonizes WNT/beta-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma. Cancer Biol Ther 10(6):617-624. doi: http://www.ncbi.nlm.nih.gov/pubmed/20603606
49. Lee JM, Dedhar S, Kalluri R, Thompson EW (2006) The epithelial- mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172(7):973-981. doi: 10.1083/jcb.200601018
50. Maugeri-Sacca M, Vigneri P, De Maria R (2011) Cancer stem cells and chemosensitivity. Clin Cancer Res 17(15):4942-4947. doi: 10.1158/1078-0432.CCR- 10-2538
51. Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C, Kato S, Tomida S, Suzuki M, Osada H, Takahashi T (2012) NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 21(3):348-361. doi: 10.1016/j.ccr.2012.02.008
52. Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, Tang L, Chen G, Basak GW, Kipps TJ (2012) ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One 7(3):e31127. doi: 10.1371/journal.pone.0031127
53. Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ (2011) ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk Res 35(10):1390-1394. doi: 10.1016/j.leukres.2011.06.021